IU study: Vaccine protects most cancer patients from COVID-19, but risk remains higher for patients with blood cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Using the nation’s largest COVID-19 data resource, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID-19. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough infections after receiving the vaccine.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login